Some Traders Are Very Bearish on Oxford Immunotec Global PLC (OXFD) After Forming Wedge Down Pattern

December 7, 2017 - By Vivian Park

Investors sentiment decreased to 1.27 in 2017 Q2. Its down 0.56, from 1.83 in 2017Q1. It dived, as 10 investors sold Oxford Immunotec Global PLC shares while 20 reduced holdings. 8 funds opened positions while 30 raised stakes. 19.91 million shares or 1.07% more from 19.70 million shares in 2017Q1 were reported.
Legal General Group Incorporated Public Llc holds 0% or 6,370 shares. 104,257 were reported by Neuberger Berman Gp Ltd Co. 703,378 were accumulated by Grandeur Peak Limited Liability Co. State Street Corp holds 447,104 shares or 0% of its portfolio. 13,345 are owned by Voya Investment Mngmt. 179,415 are owned by Penn Mgmt. Tiverton Asset Mngmt Ltd Liability Corp stated it has 0.18% in Oxford Immunotec Global PLC (NASDAQ:OXFD). 894,388 were reported by Axa. Ny State Common Retirement Fund reported 22,300 shares. Spark Invest Mngmt Limited Liability Corporation reported 0.16% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Morgan Stanley has invested 0% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). 524,509 are owned by First Light Asset Management Llc. Fosun, a Hong Kong-based fund reported 237,783 shares. Cortina Asset Management Ltd Liability reported 0.36% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). Northwestern Mutual Wealth Management, Wisconsin-based fund reported 193 shares.

Since June 15, 2017, it had 0 insider purchases, and 1 sale for $61,305 activity.

The stock of Oxford Immunotec Global PLC (OXFD) formed a down wedge with $13.36 target or 4.00 % below today’s $13.92 share price. The 6 months wedge indicates high risk for the $357.12M company. If the $13.36 price target is reached, the company will be worth $14.28 million less.
Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 11% and 15%. The average rise is 32% and the decline is 15%. The falling wedges has high throwback and pullback rate: 56%, 69% and the percent of wedges meeting target is not very high.

The stock decreased 1.90% or $0.27 during the last trading session, reaching $13.92. About 105,114 shares traded. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 54.26% since December 8, 2016 and is uptrending. It has outperformed by 37.56% the S&P500.

Analysts await Oxford Immunotec Global PLC (NASDAQ:OXFD) to report earnings on February, 27. They expect $-0.34 EPS, down 54.55 % or $0.12 from last year’s $-0.22 per share. After $-0.24 actual EPS reported by Oxford Immunotec Global PLC for the previous quarter, Wall Street now forecasts 41.67 % negative EPS growth.

Oxford Immunotec Global PLC (NASDAQ:OXFD) Ratings Coverage

Among 4 analysts covering Oxford Immunotec (NASDAQ:OXFD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oxford Immunotec had 8 analyst reports since July 19, 2017 according to SRatingsIntel. Robert W. Baird maintained Oxford Immunotec Global PLC (NASDAQ:OXFD) rating on Thursday, October 19. Robert W. Baird has “Buy” rating and $22.0 target. The firm has “Buy” rating given on Wednesday, July 19 by Cowen & Co. BTIG Research initiated the shares of OXFD in report on Thursday, September 28 with “Buy” rating. Cowen & Co maintained the stock with “Buy” rating in Wednesday, August 16 report. Cowen & Co maintained it with “Buy” rating and $19.0 target in Wednesday, September 27 report. As per Tuesday, October 31, the company rating was maintained by Robert W. Baird. Cowen & Co maintained Oxford Immunotec Global PLC (NASDAQ:OXFD) rating on Tuesday, October 31. Cowen & Co has “Buy” rating and $19.0 target.

More notable recent Oxford Immunotec Global PLC (NASDAQ:OXFD) news were published by: which released: “Oxford Immunotec Announces National Reimbursement for the T-SPOTĀ®.TB Test in …” on June 22, 2017, also with their article: “Oxford Immunotec Global’s (OXFD) CEO Peter Wrighton-Smith on Q3 2017 Results …” published on October 31, 2017, published: “Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q1 2017 Results …” on May 02, 2017. More interesting news about Oxford Immunotec Global PLC (NASDAQ:OXFD) were released by: and their article: “Oxford Immunotec Global’s (OXFD) CEO Peter Wrighton-Smith on Q2 2017 Results …” published on August 01, 2017 as well as‘s news article titled: “Oxford Immunotec Appoints Richard Wenstrup, MD, as Chief Medical Officer” with publication date: July 24, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.